Selbyville, Delaware, Oct. 31, 2023 (GLOBE NEWSWIRE) --
Antibiotic Resistance Market size could reach USD 13.6 billion by 2032, according to the latest research report by Global Market Insights Inc. As per the report, the high prevalence rate of healthcare-associated infections will favor market dynamics over 2023-2032.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/6499
Hospital-acquired infections (HAIs) often involve antibiotic-resistant bacteria, leading to longer hospital stays, increased healthcare costs, and higher mortality rates. The U.S. Department of Health and Human Services data suggests that on any given occasion, approximately 1 in 31 hospitalized patients experience infections associated with their hospital care. These infections result in tens of thousands of fatalities and impose billions of dollars in expenses on the healthcare system in the United States annually. Alarming statistics associated with HAIs have prompted healthcare institutions to seek advanced solutions for infection control and prevention, including new antibiotics and alternative treatment approaches.
Antibiotic resistance to bloodstream infections will stimulate industry expansion
The antibiotic resistance market from bloodstream infection segment could garner significant gains between 2023 and 2032. The escalating incidence of bloodstream infections significantly contributes to the progression of the industry. Bloodstream infections often necessitate the use of antibiotics, and the increasing prevalence of drug-resistant pathogens complicates treatment. For instance, the rise of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections underscores the urgency for novel antibiotics. This heightened demand for effective therapies to combat bloodstream infections propels research and investment in antibiotic development.
Prevalence of S.aureus pathogen will bring about lucrative gains
The antibiotic resistance market from S. aureus segment size could exhibit a commendable CAGR over 2023-2032. The increasing resistance of Staphylococcus aureus (S. aureus) to antibiotics is a significant driver of the industry. S. aureus, including MRSA strains, causes severe and often drug-resistant infections. In a recent study published in September 2023 in the journal Zoonoses, scientists conducted an assessment of the occurrence, virulence, antibiotic resistance, and genetic characteristics of methicillin-resistant Staphylococcus aureus (MRSA) present in ready-to-eat (RTE) food items. Surging incidences of MRSA infections in healthcare settings, communities, and livestock have highlighted the urgency for novel antibiotics. This growing challenge in treating S. aureus infections fuels research and development efforts.
Resistance to oxazolidinones to boost industry revenue streams
The oxazolidinones antibiotic resistance market is primarily driven by the emergence of resistant bacterial strains, notably methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). These pathogens, traditionally susceptible to Oxazolidinones, have developed resistance, necessitating the development of new drugs. Instances of Oxazolidinone resistance have been reported worldwide, emphasizing the need for innovative antibiotics. This resistance challenge propels research and investment in Oxazolidinone antibiotics.
Europe to dominate the regional outlook
Europe antibiotic resistance market is experiencing substantial gains due to several factors. Europe faces rising rates of antibiotic-resistant infections, with notable instances of extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant bacteria. Additionally, stringent regulations and government initiatives in the region have spurred research and development in the field. The urgent need for effective antibiotics to combat these resistant strains is driving investment and innovation.
Request for Report Customization @ https://www.gminsights.com/roc/6469
Antibiotic resistance market leaders
Major companies in the industry are WOCKHARDT, Paratek Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Merck & Co. Inc., Tetraphase Pharmaceuticals, Inc., MELINTA THERAPEUTICS, AbbVie, Inc., Theravance Biopharma, ACHAOGEN, INC., Seres Therapeutics, Entasis therapeutics, Pfizer, Inc.
Partial Table of Contents (ToC) of the report:
Chapter 3 Antibiotic Resistance Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of antibiotic resistant infections
3.2.1.2 Growing need for new antibiotic therapies
3.2.1.3 Increasing investment for research and development of novel antibiotics
3.2.1.4 Increasing global public health concern and awareness
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of therapeutics
3.2.2.2 Complex regulatory and development process
3.3 Growth potential analysis
3.3.1 By disease
3.3.2 By pathogen
3.3.3 By drug class
3.3.4 By mechanism of action
3.3.5 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Browse Our Reports Store - GMIPulse @ https://www.gminsights.com/gmipulse
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
